This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary Therapeutic Protein and Peptide mRNA Display Platform
BioVenic offers an mRNA display platform for the discovery and optimization of veterinary therapeutic proteins and peptides, supporting the development of novel protein- and peptide-based therapies for animal health and various animal diseases. Our platform covers the complete cell-free workflow—custom randomized DNA library design and synthesis, transcription and puromycin ligation, in vitro translation, affinity selection by co-immunoprecipitation, and RT-PCR regeneration with iterative enrichment rounds. We support tailored discovery programs from consultation and library design through high-throughput screening, data analysis, reporting, and after-sales technical support to deliver validated, high-affinity candidate ligands.
mRNA Display Platform Overview
The mRNA display is a tool for generating a diversity of protein and peptide libraries (ranging from thousands to trillions of unique sequences) for in vitro selection and direct evaluation. At BioVenic, we offer a specialized mRNA display platform for clients to discover therapeutic and novel proteins and peptides targeting various animal diseases. This method selects and evolves polypeptides with specialized functional properties through four main steps. At the end of this process, the library will be enriched with functional sequences. Cloning and sequencing will identify the selected functional proteins or peptides. mRNA display facilitates the discovery of new functional proteins or peptides without the need for prior design.
Fig.1 The veterinary therapeutic protein and peptide mRNA display selection cycle. (BioVenic Original)
mRNA Display Services
| Description | Services | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
mRNA Display Platform Features
- mRNA display can generate libraries containing trillions of unique protein and peptide sequences.
- Each peptide or protein is physically linked to its encoding mRNA, allowing for immediate identification of the sequence following selection.
- This technology eliminates the need for living cells since the entire selection process occurs in a test tube.
- Successful sequences from each selection round can be immediately amplified and subjected to additional rounds of selection.
- The technology can be scaled up or down easily, and the selection conditions can be extensively modified.
BioVenic also applies other cell-free systems to discover therapeutic proteins and peptides, including the ribosomal display, and DNA display. Please find the following links.
Service Workflow
BioVenic specializes in providing comprehensive services for the development of veterinary protein and peptide drugs using mRNA display technology. This cutting-edge approach enables the discovery and optimization of high-affinity ligands with potential therapeutic applications. Our services encompass consultation, mRNA display library construction, screening, analysis and reporting, and after-sales support. Additionally, BioVenic offers a one-stop solution for the development of veterinary therapeutic proteins and peptides through its extensive display services, tailored to meet the unique needs of our clients.
Fig.2 The procedural framework for mRNA display services in veterinary therapeutic protein and peptide discovery. (BioVenic Original)
Related Research
A previous study utilizes a two-stage mRNA display screening strategy to identify and optimize a high-affinity peptide that potently inhibits the MDM2-p53 and MDMX-p53 interactions. Addressing the sequence-coverage limitations of traditional phage display libraries, the researchers first screened a 16-mer randomized library using cell-free in vitro translation, followed by a second-stage screening of a 12-mer partially randomized library incorporating conserved core hydrophobic residues (Phe, Trp, and Leu) with increased selection stringency. This approach yielded an optimized 12-amino-acid peptide named MIP (MDM2 Inhibitory Peptide), which demonstrated 29-fold and 13-fold greater inhibitory potency against the MDM2-p53 and MDMX-p53 interactions compared to the reference peptide DI, respectively. Furthermore, adenovirus-mediated expression of a thioredoxin-fused MIP in living cells successfully stabilized p53, activated the downstream p53 pathway, and inhibited tumor cell proliferation in a p53-dependent manner, thereby validating the efficacy of multi-stage mRNA display for rapidly isolating high-affinity antagonists targeting critical protein-protein interactions.
Fig. 3 Schematic representation of in vitro selection of MDM2-binding peptides using mRNA display.1
Why Choose Us?
Expertise in mRNA Display
Our team specializes in an mRNA display platform designed for veterinary applications. We excel in discovering therapeutic proteins and peptides to advance animal health.
Simplified Genotype Identification
Direct linkage of proteins/peptides to their mRNA simplifies genotype identification, reducing the time required for discovery to validation and eliminating the need for further decoding steps.
Controlled, Customizable Selection Conditions
The cell-free system permits selections under controlled, customizable conditions that can mimic various physiological or pathological states, enhancing the real-world applicability of the proteins/peptides.
Versatility for Various Applications
The flexibility of mRNA display makes it suitable for both high-throughput industrial applications and targeted, specialized research projects.
Comprehensive Service Offering
We provide a full range of services from initial consultation and project design to execution, analysis, and reporting, ensuring comprehensive support throughout protein/peptide discovery process.
Advanced Technology and Facilities
We own state-of-the-art technologies and facilities for veterinary therapeutic protein and peptide discovery, which ensures high-quality and reliable results.
Case Study
Researchers applied an mRNA display platform to find a ligand against a veterinary disease-relevant target: a trillion-member randomized DNA library was transcribed, ligated to a puromycin-bearing linker, and translated in vitro so that each macrocyclic peptide became covalently attached to its own encoding mRNA. The fusion library was panned against the bead-immobilized target across six iterative rounds of affinity selection with increasing stringency, and retained binders were recovered by RT-PCR. High-throughput sequencing followed by similarity clustering revealed strong convergence: as shown in the chart, one peptide family dominated the final pool, two further families were clearly enriched at lower levels, and the remainder distributed across minor families and unclustered sequences. The dominant families each carried a conserved binding motif, confirming genuine target-driven selection.
Fig. 4 Relative Abundance of Enriched Peptide Families
Frequently Asked Questions
Q: What types of targets are best suited for our mRNA display platform in veterinary drug discovery?
A: Our mRNA display platform can accommodate a wide range of targets, including soluble proteins, cell-surface receptors, and complex disease-related enzymes. For specific target preparation requirements or unconventional molecular conformations, we recommend consulting our technical support team directly to evaluate feasibility.
Q: How many rounds of in vitro selection are typically performed to isolate high-affinity candidates?
A: The selection process usually involves 3 to 6 successive rounds of panning and amplification to effectively enrich high-affinity peptide or protein binders. The exact number is dynamically adjusted based on library diversity and target binding affinity, details of which can be discussed with our technical specialists.
Q: What form of starting materials or target information must clients provide to initiate the project?
A: Clients are generally required to supply the target protein of interest, its sequence, or relevant expression constructs alongside any specific binding criteria. If you lack purified target proteins or need assistance with upstream preparation, please reach out to our technical support to work out a customized solution.
Q: What is the standard deliverable format upon the successful completion of an mRNA display screening project?
A: Deliverables typically include enriched DNA sequences, affinity characterization data, candidate ranking reports, and a selected pool of top-performing peptide or protein leads. For downstream validation or scale-up expression options, feel free to contact our technical support team for further details.
BioVenic offers an innovative mRNA display system for the discovery of veterinary therapeutic proteins and peptides. Our solutions help customers overcome challenges in the protein and peptide discovery process. For inquiries or more information about our services, feel free to reach out to us. We are dedicated to providing expert support for your research and collaborating to advance the field of veterinary therapeutic protein and peptide development.
Reference
- Shiheido, Hirokazu, et al. "mRNA display selection of an optimized MDM2-binding peptide that potently inhibits MDM2-p53 interaction." PloS one 6.3 (2011): e17898. https://doi.org/10.1371/journal.pone.0017898. Used under CC BY 4.0. Without Modification.